Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Conestoga Micro Cap Composite. This analysis is provided for institutional research purposes only and is not investment advice.
"Conestoga's Micro Cap strategy underperformed in Q2 as speculative stocks led gains. Industrials faced political and supply chain headwinds while biotech holdings struggled with funding pressures and inventory destocking."
Conestoga's Micro Cap Composite declined 1.53% in Q2 2023, underperforming the Russell Microcap Growth Index return of 6.35%. The portfolio faced headwinds from speculative, unprofitable companies leading market gains during the quarter. Industrials was the most challenging sector with SoundThinking declining 44% after Chicago's new mayor threatened to eliminate the city's gunshot detection contract, while Mercury Systems struggled with supply chain disruptions and defense program delays. Healthcare holdings faced mixed results as biotech companies experienced pressure from challenging funding environments and inventory destocking, though some positions like Vericel and U.S. Physical Therapy delivered strong performance. Technology positions were pressured by Olo and new addition Planet Labs. Positive contributors included Construction Partners benefiting from infrastructure spending and Digi International beating expectations. The manager maintains conviction in portfolio quality despite near-term challenges, expecting biotech conditions to improve in 2024 and supply chain constraints to ease. The strategy continues to focus on high-quality companies with sustainable growth positioned for long-term outperformance.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager demonstrates moderate-high conviction through maintaining positions despite political headwinds (SoundThinking), adding new positions (Planet Labs), and providing specific company-level analysis with clear investment theses. The 25-40 holding range and detailed individual position commentary support this conviction level, though the diversified nature prevents a higher score.
Growth Outlook
The manager acknowledges current market challenges but expresses optimism about future conditions, particularly expecting biotech industry improvement in 2024 and supply chain constraint resolution. The tone is cautiously constructive despite near-term headwinds.
Risk Appetite
The portfolio maintains existing positions despite underperformance and adds new positions like Planet Labs, but the manager sold Health Catalyst due to business model concerns. Overall positioning appears steady with selective adjustments rather than aggressive risk-taking.
Capital Deployment
The manager added Planet Labs as a new position and made five additions to existing positions, but also sold Health Catalyst completely and made four trims. This represents modest net deployment activity with no clear directional bias in cash levels.
Forward Guidance
The manager provides specific forward-looking guidance expecting biotech conditions to improve in 2024, supply chain issues to resolve, and cost reduction programs to drive margin improvements. This represents a moderately positive deployment bias for the future.
Language Signal
Language includes positive terms like 'strong start,' 'robust demand,' and 'expect improved growth' but is balanced with risk language around 'challenging funding environment,' 'pressure,' and 'weakness.' Slightly more constructive than bearish overall.
Perceived Risk
The manager identifies multiple specific risks including challenging biotech funding environments, health system budget degradation, supply chain constraints, and political risks. These risks are discussed in detail with specific company impacts, indicating high perceived risk in the current environment.
Opportunity Density
The manager identifies selective opportunities like Planet Labs and maintains conviction in existing holdings, but acknowledges challenging conditions across multiple sectors. The addition of one new position while selling another suggests moderate opportunity availability requiring selectivity.
Time Horizon
The manager explicitly states expectations for 2024 improvement and references the company's long-term investment horizon with typically low turnover of 20-30%. The patient approach through current headwinds and multi-year outlook for biotech recovery indicates a long-term time horizon.
